May 17, 2017 08:02 AM EDT
R&D

J&J pitch­es its top 11 drugs in the pipeline — with a peak sales promise of $1B-plus

John Carroll

Editor & Founder

Joaquin Du­a­to at an End­points News event in San Fran­cis­co on Jan­u­ary 10, 2017

Over the last six years, J&J has …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Cas­es of se­vere RSV in two Mod­er­na vac­cine can­di­dates' tri­als raise ques­tions about fu­ture

Ex­clu­sive: Two Vi­da Ven­tures co-founders ex­it the VC firm

Ear­ly da­ta on BTK de­graders sug­gest promise of next-gen ap­proach

'It's the bi­ol­o­gy, stu­pid': Re­la­tion and GSK team up on fi­bro­sis, os­teoarthri­tis

Ar­cel­lx and Gilead seek to un­seat Leg­end and J&J with mul­ti­ple myelo­ma cell ther­a­py

sponsored

The key to faster, more im­pact­ful re­search? Put pa­tients in the dri­ver’s seat

A service from the Financial Times